Cabometyx® Tablets for Advanced Kidney, Liver, and Thyroid Cancers

What Cabometyx® Is and How It Works

Cabometyx is the brand name for cabozantinib, an oral tyrosine kinase inhibitor. It targets MET, VEGFR, and AXL pathways that drive tumor growth and blood vessel formation. It is used for advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) after prior therapy, and radioactive iodine–refractory differentiated thyroid cancer (DTC). If paying cash, some people search for cabometyx without insurance to compare options.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba; prescriptions are reviewed by licensed pharmacists before dispensing. We also source through licensed, vetted international partner pharmacies to provide authentic brand medicines, a wide selection, and competitive pricing.

Cabometyx is supplied as film‑coated tablets taken by mouth once daily. Typical starting doses are 60 mg once daily for RCC and HCC monotherapy, and 40 mg once daily when combined with nivolumab for RCC first‑line therapy. Dose reductions (to 40 mg or 20 mg) are common to manage side effects. The cabometyx manufacturer in Canada is Ipsen, and cabozantinib is also approved by the European Medicines Agency (EMA). For a plain‑language overview, see What Is Cabometyx Uses And Benefits Explained.

Cabometyx tablets should be swallowed whole on an empty stomach. Take at least 1 hour before or 2 hours after food. Avoid grapefruit products, which may raise cabozantinib levels. Your prescriber will individualize dosing and adjust for interactions with strong CYP3A modulators.

Dosage and Usage

• Take once daily at the same time, with water, on an empty stomach.
• Swallow tablets whole; do not crush, chew, or split.
• Typical monotherapy start: 60 mg daily; combination with nivolumab: 40 mg daily.
• Your prescriber may reduce to 40 mg or 20 mg to manage side effects.
• Avoid grapefruit or grapefruit juice during therapy.
• If you miss a dose and the next dose is in less than 12 hours, skip the missed dose.
• If more than 12 hours remain before the next dose, take the missed dose when remembered.
• If vomiting occurs after a dose, do not retake; resume at the next scheduled time.
• Tell your care team about all medicines and supplements, especially strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin) or inducers (e.g., rifampin, carbamazepine). Dose changes may be needed.
• Discuss planned dental work or surgery; cabozantinib can impair wound healing. It may need to be held before and after procedures.

• Store at 20–25 °C (68–77 °F); short excursions 15–30 °C (59–86 °F) are acceptable.
• Keep tablets dry in the original bottle with the cap tightly closed.
• Protect from moisture and heat; do not store in a bathroom.
• Keep out of reach of children and pets.
• For travel, carry in hand luggage with the original label; bring extra for delays.
• Do not repack into pill organizers if humidity is high; consider desiccant packs.

Benefits and Savings

Cabometyx helps slow disease progression by blocking tumor signaling and angiogenesis. In advanced RCC and HCC, it improves progression‑free survival versus some earlier standards. In RCC, combining cabozantinib with nivolumab offers higher response rates than sunitinib in many patients. Once‑daily tablets reduce clinic time compared with infusions.

Buying through a Canadian pharmacy can cut the cabometyx price. Many patients see 60–80% savings versus typical US costs. Multi‑month supplies and occasional bulk promotions can reduce the per‑month cabometyx cost. If you shop as cabometyx no insurance, you can still order with a valid prescription.

For current offers, see our cabometyx coupon page.

We carry brand oncology medicines at Canadian prices and review prescriptions carefully for safety. Dose consistency and timely refills support outcomes. You can set simple reorder reminders so therapy is not interrupted.

Side Effects and Safety

• Diarrhea
• Fatigue or weakness
• Nausea or vomiting
• Mouth sores (stomatitis)
• Decreased appetite and weight loss
• High blood pressure
• Hand‑foot skin reaction (palmar‑plantar erythrodysesthesia)
• Abdominal pain
• Change in taste
• Elevated liver enzymes
• Hypothyroidism
• Hair or skin color changes

Serious risks include bleeding, blood clots, impaired wound healing, gastrointestinal perforation or fistula, proteinuria, reversible posterior leukoencephalopathy syndrome, and osteonecrosis of the jaw. Dental evaluation before starting can help reduce jaw risk. Report severe headache, chest pain, black stools, sudden shortness of breath, or signs of infection. Pregnancy should be avoided; use effective contraception during treatment and for the recommended period after the last dose.

Onset Time

Side effects such as diarrhea, fatigue, or hand‑foot reaction can appear within the first 1–3 weeks. Blood pressure often rises early, so monitoring starts soon after initiation. Thyroid function, liver enzymes, and urine protein are checked regularly.

Tumor response is assessed over time. Many patients have disease control within 4–8 weeks, with imaging typically scheduled every 8–12 weeks. Some responses deepen with continued therapy as dosing stabilizes. Your oncology team interprets scans and labs in the context of your overall treatment plan.

Compare With Alternatives

Other first‑line options for advanced RCC include pembrolizumab plus axitinib, and nivolumab plus cabozantinib. For some patients, sunitinib or pazopanib are considered. Choice depends on risk stratification, co‑morbidities, and tolerance of side‑effect profiles.

Immunotherapy combinations offer durable responses in a subset of patients. The regimen of avelumab with axitinib is one example; learn more about Bavencio® as an immuno‑oncology option used in RCC combinations.

For previously treated HCC, options include regorafenib, ramucirumab (for AFP‑high disease), or cabozantinib. In DTC, other TKIs such as lenvatinib are used. Your oncology specialist weighs efficacy, toxicity, and prior therapies when comparing these alternatives.

Combination Therapy

• Nivolumab plus cabozantinib for first‑line advanced RCC. Cabozantinib is usually 40 mg daily in this regimen.
• Cabozantinib as monotherapy after prior therapies in RCC or HCC.
• Assess blood pressure, thyroid function, and liver enzymes regularly when combining with immunotherapy.
• Discuss any CYP3A inhibitors/inducers; dose adjustments may be required to manage exposure and toxicity.
• Before invasive dental or surgical procedures, a temporary interruption is often planned to reduce wound‑healing complications.

Patient Suitability and Cost-Saving Tips

Cabometyx may suit adults with advanced RCC, previously treated HCC, or RAI‑refractory DTC. It may not be appropriate with uncontrolled hypertension, recent significant bleeding, untreated fistulas, or high risk for GI perforation. Caution is needed with severe hepatic impairment. A dental check is prudent before starting to lower jaw‑related risks.

Those taking strong CYP3A modulators may need dose changes. Avoid grapefruit products. Discuss pregnancy plans and contraception. Your oncology team will tailor dosing and monitoring based on response and tolerability.

To manage expenses, consider 90‑day fills where appropriate. Bulk promotions can lower the per‑month cabometyx cost, and simple reorder reminders help prevent gaps. Availability of generic cabozantinib varies by market; when stocked, generic cabometyx may reduce out‑of‑pocket spending. If you are comparing cabometyx out of pocket offers, review strength, quantity, and manufacturer details.

Authoritative Sources

Manufacturer product page for CABOMETYX (cabozantinib)

FDA approval history and prescribing information for CABOMETYX

Health Canada Drug Product Database (search “Cabometyx”)

Order Cabometyx® from Youdrugstore.com: add to cart, upload your prescription, and we ship with prompt, express shipping.

This page is for educational purposes and does not replace professional medical advice. Always speak with your healthcare provider about diagnosis, treatment choices, and dosing.